Anna Riziki Moshe-smith, | |
11615 Highway 99 Apt C102, Everett, WA 98204-7825 | |
(253) 326-2771 | |
Not Available |
Full Name | Anna Riziki Moshe-smith |
---|---|
Gender | Female |
Speciality | Licensed Vocational Nurse |
Location | 11615 Highway 99 Apt C102, Everett, Washington |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1588318927 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
164X00000X | Licensed Vocational Nurse | LP60958037 (Washington) | Primary |
Mailing Address | Practice Location Address |
---|---|
Anna Riziki Moshe-smith, 11615 Highway 99 Apt C102, Everett, WA 98204-7825 Ph: (253) 326-2771 | Anna Riziki Moshe-smith, 11615 Highway 99 Apt C102, Everett, WA 98204-7825 Ph: (253) 326-2771 |
News Archive
A $6 million, five-year grant from the Parisian Fondation Leduq has set up a transatlantic effort to study ways to help damaged hearts repair themselves, using stem cells from bone marrow, bloodstream, and adult heart tissue.
The Board of Directors of Sinobiomed Inc. is pleased to announce the sale of the Company's wholly-owned BVI subsidiary, Wanxin Bio-Technology Limited and its Chinese subsidiaries, Shanghai Wanxin Bio-Pharmaceutical Co Ltd. and Shanghai Bio-Science Cosmetic Co Ltd.
The antibiotic drug minocycline yields "modest" but meaningful improvements in functioning and mood for children with fragile X syndrome (FXS), reports a study in the April Journal of Developmental & Behavioral Pediatrics, the official journal of the Society for Developmental and Behavioral Pediatrics.
Authentidate Holding Corp., a worldwide provider of secure Health Information Exchange, workflow management services and telehealth solutions, today announced that Elmora Healthcare, a supplier of home medical equipment, medical supplies and care services, selected Authentidate's Inscrybe® Healthcare web-based service to expedite processing of patient care orders with referring physicians.
GlaxoSmithKline (GSK), the World Health Organisation's Special Programme for Research and Training in Tropical Diseases (WHO-TDR) and the Medicines for Malaria Venture (MMV) today announced the signing of a collaborative agreement, to develop a new-fixed dose artemisinin combination therapy drug (ACT), combining chlorproguanil, dapsone and artesunate (CDA) for the treatment of malaria.
› Verified 8 days ago